Clinical validation Adela has clinically validated methylome-based MRD and MCED tests with published results in Annals of Oncology and npj Precision Oncology, signaling credibility and potential for expanding oncology diagnostics partnerships and payer discussions.

Expansion ready Recent launches and near-commercialization of head and neck MRD test, plus ongoing MCED development, indicate a growth trajectory and opportunities to cross-sell tissue-free MRD solutions to cancer centers expanding MRD workflows.

Strategic partnerships Evidence of collaboration with Dendi, Inc. for commercialization and strong investor backing from OrbiMed demonstrates a validation network and potential co-sell or integration opportunities with diagnostic distributors and biopharma collaborators.

Data and tech leverage Use of broad methylome enrichment and data technologies suggests opportunities to position Adela as a companion diagnostic ally for immunotherapy programs and multi-cancer screening pilots at hospitals and CROs.

Financial health signals Revenue in the hundreds of millions with substantial funding and a high-profile leadership award for the CSO enhances credibility for enterprise sales, negotiations with hospital systems, and multi-site deployment discussions.